A phase II study in advanced gastro-esophageal cancer using epirubicin and cisplatin in combination with continuous infusion 5-fluorouracil (ECF)

Findlay, Michael; Cunningham, David; Norman, A.; Mansi, Janine; Nicolson, M. C.; Hickish, Tamas; Nicolson, V; Nash, A. G.; Sacks, N. P. M.; Ford, H. T.; Carter, R.; Hill, A

doi:10.1093/oxfordjournals.annonc.a058932

Cited by 244 publications

(154 citation statements)

References 21 publications

Supporting

Mentioning

145

Contrasting

Unclassified

Order By: Relevance

“…[2][3][4][5] However, none of the combination regimens have yet demonstrated a prolongation of survival as compared with 5-fluorouracil alone; [6][7][8] accordingly new active chemotherapy regimens are needed. Irinotecan hydrochloride (CPT-11) is a water-soluble, semisynthetic derivative of camptothecin (CPT) that retains the original antitumor activity of CPT, but has lower toxicity.…”

Section: Introductionmentioning

confidence: 99%

Combination chemotherapy of irinotecan plus cisplatin for advanced gastric cancer: efficacy and feasibility in clinical practice

et al. 2001

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Combination chemotherapy of irinotecan plus cisplatin for advanced gastric cancer: efficacy and feasibility in clinical practice

et al. 2001

View full text Add to dashboard Cite

“…Recently, the Royal Marsden Hospital reported the results of a phase II study on oesophago-gastric cancer patients treated with CDDP, infusional 5-FU and epiADR (ECF regimen) (Findlay et al, 1994). The activity of this regimen (71% of response rate) and the acceptable toxicity contributed to launch a large randomized trial in which ECF was compared to the standard FAMTX.…”

Section: Discussionmentioning

confidence: 99%

Infusional 5-fluorouracil, cisplatin and mitomycin C in advanced gastric cancer: A low cost effective regimen

Cascinu¹,

Baldelli²,

Catalano³

et al. 2002

Br J Cancer

View full text Add to dashboard Cite

Recently, we reported a highly active regimen in advanced gastric cancer including a weekly administration of cisplatin, epidoxorubicin, leucovorin, 5-fluorouracil with the support of filgrastim. In order to simplify the administration and to decrease the toxicity of these drugs, mainly epidoxorubicin-induced alopecia, we designed a regimen including an infusional 5-fluorouracil schedule according to the de Gramont regimen, cisplatin and mitomycin C replacing epidoxorubicin. Forty-five patients with advanced or metastatic gastric cancer were treated with cisplatin 50 mg m 72 i.v. on day 1, every 2 weeks, 6S-stereoisomer-leucovorin 100 mg m 72 i.v. followed by 5-fluorouracil 400 mg m 72 i.v. bolus and 600 mg m 72 i.v. in a 22-h infusion, on days 1 and 2, every 2 weeks, and mitomycin C 7 mg m 72 i.v. bolus on day 2, every 6 weeks. Grades 3 -4 toxicities (National Cancer Institute-Common Toxicity Criteria) consisted mainly of neutropenia and thrombocytopenia. Five patients had a complete response and 16 had a partial response for an overall response rate of 46.7% (95% confidence interval, 32.1 -61.2%). The median survival was 11 months. The combination of cisplatin, 5-fluorouracil and leucovorin according to de Gramont, and mitomycin C seems to be an active and safe regimen in the treatment of advanced gastric cancer. Because of its low cost it may be suggested for patients not enrolled into clinical trials.

show abstract

“…Most are triple therapies incorporating 5FU and cisplatin with either epirubicin or paclitaxel. Response rates of 48 -70% have been achieved (Kim et al, 1993;Ilson et al, 1998) with a 2-year survival of 13.5% (Findlay et al, 1994); however, in general, the responses are often short lived and these treatments are associated with varying degrees of toxicity.…”

mentioning

confidence: 99%

Combination chemotherapy in advanced gastrointestinal cancers: ex vivo sensitivity to gemcitabine and mitomycin C

et al. 2003

View full text Add to dashboard Cite

Advanced or metastatic disease is common in both oesophagogastric and colorectal cancers, with poor 5-year survival despite palliative chemotherapy. We have investigated the sensitivity of gastrointestinal tumours to gemcitabine in combination with mitomycin C (GeM), using a modified ex vivo ATP-based tumour chemosensitivity assay (ATP-TCA). Tumour material from 41 colorectal and 22 oesophagogastric cancers were assessed. The GeM combination showed variable but definite activity in most of the samples tested. The results show that GeM achieves 495% inhibition at concentrations within the range achievable clinically in 60% of colorectal tumours (21 out of 35) and 38% of oesophagogastric tumours (five out of 13) tested. We did not identify any significant difference in sensitivity using concurrent or sequential exposure of tumour-derived cells to these two drugs. The results from this study suggest that GeM may be a useful combination in the treatment of advanced gastrointestinal malignancy.

show abstract

A phase II study in advanced gastro-esophageal cancer using epirubicin and cisplatin in combination with continuous infusion 5-fluorouracil (ECF)

Abstract: The ECF regimen displays high anti-tumour activity with moderate toxicity in patients with gastric cancer and in some cases enabled resection of previously inoperable tumours.

Cited by 244 publications

References 21 publications

Combination chemotherapy of irinotecan plus cisplatin for advanced gastric cancer: efficacy and feasibility in clinical practice

Combination chemotherapy of irinotecan plus cisplatin for advanced gastric cancer: efficacy and feasibility in clinical practice

Infusional 5-fluorouracil, cisplatin and mitomycin C in advanced gastric cancer: A low cost effective regimen

Combination chemotherapy in advanced gastrointestinal cancers: ex vivo sensitivity to gemcitabine and mitomycin C

Contact Info

Product

Resources

About